Congress: ISPOR Europe 2016
Year: 2016
Disease: Oncology
Subcategory: Minimization of costs
Objective: To perform a cost minimization analysis comparing the costs of native asparaginase therapy versus pegaspargase therapy in patients diagnosed with acute lymphoblastic leukemia (ALL) from the perspective of the National Health System.
The study is supported by Shire.
DOI: https://doi.org/10.1016/j.jval.2016.09.2243
